Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
Recently, several authors have proposed the use of linear regression models in cost-effectiveness analysis. In this paper, by modelling costs and outcomes using patient and Health Centre covariates, we seek to identify the part of the cost or outcome difference that is not attributable to the treatment itself, but to the patients' condition or to characteristics of the Centres. Selection of the covariates to be included as predictors of effectiveness and cost is usually assumed by the researcher. This behaviour ignores the uncertainty associated with model selection and leads to underestimation of the uncertainty about quantities of interest. We propose the use of Bayesian model averaging as a mechanism to account for such uncertainty about the model. Data from a clinical trial are used to analyze the effect of incorporating model uncertainty, by comparing two highly active antiretroviral treatments applied to asymptomatic HIV patients. The joint posterior density of incremental effectiveness and cost and cost-effectiveness acceptability curves are proposed as decision-making measures.
Negrín
Miguel A
MA
Department of Quantitative Methods, University of Las Palmas de G.C, 35017 Las Palmas de Gran Canaria, Spain. mnegrin@dmc.ulpgc.es
Vázquez-Polo
Francisco-José
FJ
D000328:Adult; D001294:Attitude to Health; D001499:Bayes Theorem; D003362:Cost-Benefit Analysis / Q000379:methods* / Q000706:statistics & numerical data; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D017059:Models, Econometric; D010043:Outcome and Process Assessment, Health Care / Q000191:economics*; D019057:Quality-Adjusted Life Years; D013030:Spain; D035501:Uncertainty